Skip to content
OpenCapital
Get started

Stoke Therapeutics, Inc. STOK Proceeds From Issuance Of Common Stock In Controlled Equity Offering Sales Agreement

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$1.89B+436%

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0×0.0×
Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept stok:ProceedsFromIssuanceOfCommonStockInControlledEquityOfferingSalesAgreement.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Stoke Therapeutics, Inc.'s proceeds from issuance of common stock in controlled equity offering sales agreement?
Stoke Therapeutics, Inc. (STOK) reported proceeds from issuance of common stock in controlled equity offering sales agreement of $80.66M in Q1 2026.